Circulating Tumor DNA in Surgical Lung Cancer Patients

A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Lung Cancer Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03081741

Enrollment

500

Registered

2017-03-16

Start date

2017-05-03

Completion date

2020-03-18

Last updated

2017-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Brief summary

Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.

Detailed description

Studies have shown the feasibility of detecting mutation status by blood circulating tumor DNA (ctDNA) in lung cancer patients. The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Aged 18 to 80 years Undergo radical surgery Histologically confirmed diagnosis of lung cancer Considered primary lung cancer by clinical criteria Patients must have given written informed consent

Exclusion criteria

Unable to comply with the study procedure Malignant tumor history Patients who received any treatment prior to resection Unqualified blood samples

Design outcomes

Primary

Measure	Time frame	Description
Effect of surgery on ctDNA of lung cancer patients	before surgery and 7days after surgery	Changes of blood ctDNA of lung cancer patients before and after surgery.

Countries

China

Contacts

Primary ContactChaoyu Liu, PhD

lcy@genehe.com+8675588858978-808

Backup ContactXiaohua Li, PhD

lixiaohua@genehe.com+8675588858978-808

Outcome results